Literature DB >> 32450558

Defining "Haemodynamic Significance" of the Patent Ductus Arteriosus: Do We Have All the Answers?

Aisling Smith1, Afif F El-Khuffash2,3.   

Abstract

Optimum management of the patent ductus arteriosus (PDA) in preterm infants remains one of the most debated topics within the field of neonatology. Despite numerous observational studies and over 60 randomized control trials, consensus on PDA management remains elusive. In order to make meaningful progress on the controversial issue of PDA management, several key factors must be thoroughly addressed; namely (1) accurate identification of infants at greatest risk of long-term morbidities from PDA exposure, (2) acceptance that the PDA is not a dichotomous entity and an individualised approach to its management is required for each neonate, (3) international consensus on what constitutes a haemodynamically significant PDA and (4) the incorporation of multi-organ assessment when evaluating the impact a PDA may pose on overall neonatal physiology. This review assesses the evidence base available supporting various therapeutic strategies for PDA, the deficits in our current knowledge on the definition of haemodynamic significance and future directions to pursue in order to more successfully address this contentious subject.
© 2020 S. Karger AG, Basel.

Entities:  

Keywords:  Haemodynamic significance; Patent ductus arteriosus; Premature infant

Year:  2020        PMID: 32450558     DOI: 10.1159/000506988

Source DB:  PubMed          Journal:  Neonatology        ISSN: 1661-7800            Impact factor:   4.035


  11 in total

Review 1.  Percutaneous Closure of Patent Ductus Arteriosus.

Authors:  Megan Barcroft; Christopher McKee; Darren P Berman; Rachel A Taylor; Brian K Rivera; Charles V Smith; Jonathan L Slaughter; Afif El-Khuffash; Carl H Backes
Journal:  Clin Perinatol       Date:  2022-01-21       Impact factor: 3.430

Review 2.  The role of furosemide and fluid management for a hemodynamically significant patent ductus arteriosus in premature infants.

Authors:  Sarah Dudley; Shawn Sen; Alison Hanson; Afif El Khuffash; Philip T Levy
Journal:  J Perinatol       Date:  2022-07-15       Impact factor: 3.225

3.  Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants.

Authors:  Souvik Mitra; Alexandra Scrivens; Adelaide M von Kursell; Tim Disher
Journal:  Cochrane Database Syst Rev       Date:  2020-12-10

4.  Platelet Counts and Patent Ductus Arteriosus in Preterm Infants: An Updated Systematic Review and Meta-Analysis.

Authors:  Gema González-Luis; Stefano Ghiradello; Pilar Bas-Suárez; Giacomo Cavallaro; Fabio Mosca; Ronald I Clyman; Eduardo Villamor
Journal:  Front Pediatr       Date:  2021-01-20       Impact factor: 3.418

5.  Predictive Value of Blood N-Terminal Pro-Brain Natriuretic Peptide Concentrations for Early Patent Ductus Closure in Very Preterm Infants.

Authors:  Solomiia Potsiurko; Dmytro Dobryanskyy; Lesya Sekretar
Journal:  J Saudi Heart Assoc       Date:  2021-01-08

Review 6.  Current Controversy on Platelets and Patent Ductus Arteriosus Closure in Preterm Infants.

Authors:  Hannes Sallmon; Natalie Timme; Begüm Atasay; Ömer Erdeve; Georg Hansmann; Yogen Singh; Sven C Weber; Elaine L Shelton
Journal:  Front Pediatr       Date:  2021-02-25       Impact factor: 3.418

7.  Editorial: Management of Patent Ductus Arteriosus in Preterm Infants.

Authors:  Begüm Atasay; Ömer Erdeve; Hannes Sallmon; Yogen Singh
Journal:  Front Pediatr       Date:  2021-04-14       Impact factor: 3.418

8.  Early N-Terminal Pro B-Type Natriuretic Peptide (NTproBNP) Plasma Values and Associations with Patent Ductus Arteriosus Closure and Treatment-An Echocardiography Study of Extremely Preterm Infants.

Authors:  Anna Gudmundsdottir; Marco Bartocci; Oda Picard; Joanna Ekström; Alexander Chakhunashvili; Kajsa Bohlin; Caroline Attner; Gordana Printz; Mathias Karlsson; Lilly-Ann Mohlkert; Jonna Karlén; Cecilia Pegelow Halvorsen; Anna-Karin Edstedt Bonamy
Journal:  J Clin Med       Date:  2022-01-27       Impact factor: 4.241

9.  Point-of-Care (POC) Urinary L-Type Fatty Acid-Binding Protein (u-LFABP) Use in Critically Ill, Very Preterm Neonates.

Authors:  Henny Adriani Puspitasari; Eka Laksmi Hidayati; Retno Palupi-Baroto; Diashati Ramadhani Mardiasmo; Rosalina Dewi Roeslani
Journal:  Int J Nephrol       Date:  2022-03-19

10.  Patent ductus arteriosus, systemic NT-proBNP concentrations and development of bronchopulmonary dysplasia in very preterm infants: retrospective data analysis from a randomized controlled trial.

Authors:  Solomiia Potsiurko; Dmytro Dobryanskyy; Lesya Sekretar
Journal:  BMC Pediatr       Date:  2021-06-19       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.